Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Anderle, C. Articles by Heide, L. Search for Related Content PubMed PubMed Citation Articles by Anderle, C. Articles by Heide, L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2008, p. 1982-1990, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.01235-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Biological Activities of Novel Gyrase Inhibitors of the Aminocoumarin Class

Christine Anderle,¹ Martin Stieger,² Matthew Burrell,³ Stefan Reinelt,² Anthony Maxwell,³ Malcolm Page,² and Lutz Heide^1*

Pharmazeutische Biologie, Pharmazeutisches Institut, Universität Tübingen, Auf der Morgenstelle 8, Tübingen D-72076, Germany,¹ Basilea Pharmaceutica AG, Grenzacherstr. 487, Basel CH-4005, Switzerland,² Department of Biological Chemistry, John Innes Centre, Colney, Norwich NR4 7UH, United Kingdom³

Received 20 September 2007/ Returned for modification 11 February 2008/ Accepted 6 March 2008

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Thirty-one aminocoumarin antibiotics derived from mutasynthesis experiments were investigated for their biological activities. Their inhibitory activities toward Escherichia coli DNA gyrase were determined in two different in vitro assays: an ATPase assay and a DNA supercoiling assay. The assays gave a similar rank order of the activities of the compounds tested, although the absolute 50% inhibitory concentrations (IC₅₀s) obtained in each assay were different. To confirm that the compounds also acted as gyrase inhibitors in vivo, reporter gene assays were carried out with E. coli by using gyrA and sulA promoter fusions with the luxCDABE operon. A strong induction of both promoters was observed for those compounds that showed gyrase inhibitory activity in the biochemical assays. Compounds carrying analogs of the prenylated benzoyl moiety (ring A) of clorobiocin that were structurally very different showed high levels of activity both in the biochemical assay and in the reporter gene assay, indicating that the structure of this moiety can be varied considerably without a loss of affinity for bacterial gyrase. The experimentally determined IC₅₀s were compared to the binding energies calculated in silico, which indicated that a shift of the pyrrole carboxylic acid moiety from the O-3'' to the O-2'' position of the deoxysugar moiety has a significant impact on the binding mode of the compounds. The aminocoumarin compounds were also investigated for their MICs against different bacterial pathogens. Several compounds showed high levels of activity against staphylococci, including a methicillin-resistant Staphylococcus aureus strain. However, they showed only poor activities against gram-negative strains.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
A major threat to therapy for human infections is the increase in the levels of antibiotic resistance and the continuing spread of nosocomial pathogens into the community (3, 21). Therefore, it is essential that new antibacterial drugs be developed. In this context, the reevaluation of previously discovered, but so far unexploited, classes of antibiotics has come into the focus of antibiotic research (31). The aminocoumarin antibiotics inhibit a well-validated drug target (DNA gyrase), but in contrast to the widely used fluoroquinolones, the aminocoumarins bind to the B subunit of the heterotetrameric gyrase enzyme. The binding site of the aminocoumarins overlaps with the ATP-binding site of gyrase, located on GyrB, and the aminocoumarins thereby inhibit the ATP hydrolysis required for ATP-dependent DNA supercoiling (25). In the same way, they inhibit DNA topoisomerase IV, which is a type II topoisomerase similar to gyrase and which is involved both in the control of DNA supercoiling and in the decatenation of daughter chromosomes after DNA replication. The aminocoumarins show strong activities against gram-positive pathogens like Staphylococcus aureus and Staphylococcus epidermidis (14, 15, 30, 37). Novobiocin (Albamycin; Upjohn) is the only aminocoumarin which has been licensed for the treatment of human infections, and its efficacy has been confirmed in several clinical trials (32, 33, 38). Aminocoumarins also show the potential for use as anticancer drugs (4, 6, 20, 22, 23, 34).

Among the limitations of the aminocoumarins are their poor solubility in water and their poor oral absorption. Their low levels of activity against gram-negative bacteria were perceived as an additional drawback at the time of their discovery (15, 30); it may be argued, however, that this could also present an advantage, since gram-negative bacteria in the gut are not affected by these drugs.

Structurally, novobiocin and the closely related aminocoumarin clorobiocin (Fig. 1) are composed of a 3-dimethylallyl-4-hydroxybenzoyl moiety (ring A), a 3-amino-4,7-dihydroxycoumarin moiety (ring B) substituted with a methyl group and a chlorine atom, respectively, and a substituted deoxysugar (ring C) (Fig. 1). The 3''-OH of the deoxysugar is esterified with a carbamoyl group in the case of novobiocin and with a 5-methylpyrrole-2-carboxyl moiety in the case of clorobiocin. In contrast to the carbamoyl group of novobiocin, the 5-methylpyrrole moiety of clorobiocin is able to occupy an additional hydrophobic pocket in the GyrB subunit and to displace two water molecules (18). Thereby, clorobiocin binds more effectively to the GyrB subunit than novobiocin. The ring A moiety interacts only via hydrophobic bonds with the B subunit of gyrase and contributes only weakly to the antibacterial activity (16). However, ring A may influence the uptake of the compound into the bacterial cell (17).

View larger version (9K): [in this window] [in a new window]

FIG. 1. Structures of novobiocin and clorobiocin.

Mutasynthesis, i.e., the feeding of synthetic precursor analogs to mutants of microbial producer strains of natural products, is an important and powerful tool for drug discovery and lead optimization. We recently generated a series of 31 new aminocoumarin compounds by addition of synthetic analogs of the ring A moiety to specific mutants of the novobiocin and clorobiocin producers (1, 2). In the current study, we utilized these compounds to investigate the structure-activity relationships of this class of gyrase inhibitors as a prerequisite for the development of aminocoumarin antibiotics with improved properties. Different biochemical and reporter gene assays, as well as a computational method and antibacterial assays, were used to examine the biological effects of these compounds, allowing a comparison of the results of these different methods. Specifically, two different biochemical assays were used, i.e., an ATPase assay and a supercoiling assay. The ATPase assay measured the ATP hydrolyzing activity of the B subunit of Escherichia coli DNA gyrase and its inhibition by aminocoumarin antibiotics (25). The supercoiling assay (24) measured the supercoiling activity of the intact E. coli gyrase heterotetramer; it exploited the fact that the formation of a DNA triplex (an alternative structure to the DNA double helix) is favored by the negative supercoiling of DNA. A plasmid containing a 20-bp insert with triplex-forming potential was partially supercoiled by the action of gyrase and subsequently captured by a biotinylated oligonucleotide which was bound to the streptavidin-coated surface of a micotiter plate. After unbound plasmids were washed out, the nucleic acids in the microtiter well were quantified by the use of a DNA-specific fluorescent dye. This assay allowed the rapid, automated determination of gyrase inhibition by the test compounds.

The experimentally obtained results were compared with the binding energies calculated from in silico docking studies by using Moloc software (www.moloc.ch). Furthermore, two reporter gene assays with living bacterial cells were used. The gyrA promoter responds to changes in the superhelical density of the DNA in the bacterial cell caused by gyrase inhibition. Therefore, fusions of this promoter to a reporter gene can be used to screen for inhibitors that attack at either subunit of gyrase (GyrA or GyrB). The SOS-inducible sulA promoter responds to agents that ultimately interfere with DNA replication (36). Inhibition of gyrase affects DNA replication and therefore leads to induction of the sulA promoter. The gyrA and sulA promoters were fused to the five-gene luxCDABE operon from Photorhabdus luminescens for facile monitoring of kinetic responses (27).

The selected compounds were further investigated for their MICs against a panel of bacterial pathogens.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Mutasynthetic generation of new aminocoumarins. Heterologous producer strains of novobiocin and the clorobiocin defective in the genes for the prenyltransferases NovQ or CloQ, respectively, were used for the mutasynthetic generation of new aminocoumarins. The prenyltransferase is required for the biosynthesis of the prenylated 4-hydroxybenzoate moiety (ring A) of novobiocin or clorobiocin (Fig. 1). Feeding of different synthetic ring A analogs to the novQ/cloQ-defective strains resulted in the formation of new aminocoumarin derivatives with modified substitution patterns. The range of new aminocoumarin antibiotics accessible from these mutasynthesis experiments was expanded by expression of the amide synthetase CouL or SimL, involved in the biosynthesis of other aminocoumarin antibiotics, and by two-step feeding strategies that successively used mutants of the novobiocin and the clorobiocin producer strains. Details of the generation of the new compounds and of their structural elucidation are described elsewhere (1, 2).

ATPase assay. The GyrB subunit used in the ATPase assay was purified from E. coli JM109 containing the GyrB subunit expression plasmid described by Hallett et al. (12). The strain was grown at 37°C in LB broth containing 50 µg/ml ampicillin to an optical density (OD) of 0.5 (A₅₉₅). Isopropyl-β-D-thiogalactopyranoside was added to a final concentration of 0.05 mM, and cell growth was continued for 4 h. The cells were centrifuged at 10,000 x g and 4°C for 15 min. The cell pellet was resuspended in 50 mM Tris-HCl (pH 7.6), 10% (wt/vol) sucrose, 1 µg/ml RNase, 1 µg/ml DNase, and 20 µg/ml lysozyme. After incubation for 30 min at room temperature, the cells were disrupted by using a French press. The cell extract was dialyzed against TE (Tris-EDTA) buffer and applied to a heparin-Sepharose column (Pharmacia). After the column was washed with TE buffer, the column was eluted with a linear gradient of 0 to 1.0 M NaCl in TE buffer. Fractions containing the GyrB subunit were identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, pooled, dialyzed against TE buffer, and loaded onto a fast-performance liquid chromatography Mono Q HR5/5 column (Pharmacia). After the column was washed with TE buffer, the column was eluted with a linear gradient of 0 to 0.2 M NaCl in TE buffer and then a linear gradient of 0.2 to 1.0 M NaCl in TE buffer. Fractions containing the GyrB subunit were identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis; pooled; dialyzed against 50 mM Tris-HCl (pH 8), 100 mM KCl, 5 mM dithiothreitol (DTT), 1 mM EDTA, and 10% (wt/vol) glycerol; frozen in liquid nitrogen; and stored at –80°C.

The ATPase assay was performed in 96-well microtiter plates, similar to a previously published method for Hsp90 (35). The reaction mixture contained 50 mM Tris-HCl (pH 7.6), 100 mM KCl, 5 mM MgCl₂, 5 mM DTT, 1 mM EDTA, and 1 mM ATP. In each well of a 96-well microtiter plate, 25 µl assay buffer was incubated with the E. coli GyrB subunit at a final concentration of 100 nM. Wells without the GyrB subunit were used as negative controls. Inhibitors, dissolved in dimethyl sulfoxide (DMSO), were added to the reaction mixtures at concentrations between 0.008 and 10 µM, such that the final DMSO concentration was 4% (vol/vol). Wells not containing any inhibitors were used as positive controls. The plates were incubated at room temperature for 1 h. To stop the reaction, 80 µl of malachite green reagent, prepared as described by Rowlands et al. (35), was added to each well, followed by the addition of 10 µl of 34% aqueous sodium citrate to prevent nonenzymatic ATP hydrolysis. After 15 min at room temperature, the A₆₂₀ was measured.

Supercoiling assay. A supercoiling assay, based on DNA triplex formation (24), was performed in black streptavidin-coated 96-well microtiter plates (Pierce). It contained 1 µg relaxed pNO1 DNA, 35 mM Tris-HCl (pH 7.5), 24 mM KCl, 4 mM MgCl₂, 2 mM DTT, 1.8 mM spermidine, 1 mM ATP, 6.5% (wt/vol) glycerol, and 0.1 mg ml^–1 bovine serum albumin in a 30-µl volume. Inhibitors were added to the reaction mixtures at concentrations between 0.01 and 100 µM, such that the final DMSO concentration was 3% (vol/vol). The reactions were initiated by the addition of 10 nM GyrA and 9.3 nM GyrB, and the reaction mixtures were incubated at 37°C for 30 min. Termination, detection, and readout were carried out as described previously (24). SigmaPlot (version 10) software was used for data analysis. Selected compounds were also assayed by the conventional gel electrophoresis method to confirm the results (24).

Reporter gene assay. The luciferase operon luxCDABE of Photorhabdus luminescence was placed under the control of the gyrA promoter of E. coli K-12 and cloned into low- to medium-copy-number plasmid pACYC184. The resulting plasmid was introduced into the hyperpermeable strain E. coli DC2 (5), in order to minimize problems of antibiotic uptake across the bacterial cell envelope. A similar construct was prepared by using the promoter of sulA from E. coli K-12. Therefore, plasmid pCGLS11 (9), which contains the genes coding for the luciferase operon (luxC, luxD, luxA, luxB, and luxE), was digested with EcoRI, and the fragment containing the whole luciferase operon was cloned into the vector pACYC184 (New England Biolabs). The resulting plasmid was linearized by partial digestion with EcoRI, filled in with the Klenow polymerase, and religated to destroy the EcoRI site 3' of the luxE gene. To delete the promoter of the chloramphenicol resistance gene, the resulting plasmid was digested with PvuII, and the band of 10.8 kb was isolated and circularized by ligation. The final plasmid, pLuxCDABE, was obtained by digesting the construct obtained as described above with EcoRI and XcmI. The band of 10.35 kb was ligated with two oligonucleotides, oligonucleotide 1 (5'-AATTCGAGCTCGGTACCCGGGCTGCAGCCATTAAA-3') and oligonucleotide 2 (5'-TTAATGGCTGCAGCCCGGGTACCGAGCTCG-3'), to introduce a polylinker in front of the luciferase operon. The promoters gyrA and sulA of E. coli were amplified from the genomic DNA of E. coli strain DH10B by PCR. The PCR primers gyrA_1 (5'-CGACATCGGGTACCTTTTTGCC-3') and gyrA_2 (5'-TCCCTCTACTGCAGCCCGGAT-3'), as well as primers sulA_1 (5'-GGTCAGGCGGTACCTGCCAAAC-3') and sulA_2 (5'-CATAATCACTGCAGCCCCTGT-3'), were used for the amplification of the corresponding promoter. The PCR fragments were digested with KpnI and PstI and cloned into the same sites of pLuxCDABE.

E. coli DC2 (5) cells with the corresponding plasmid containing the promoter of the E. coli sulA or gyrA gene fused to the luxCDABE operon were cultured overnight at 37°C in LB medium with 2 µg/ml tetracycline. The overnight culture was diluted 1:100 with LB medium without tetracycline and incubated for 1.5 h at 37°C. Aliquots (100 µl) of this preculture were placed into microtiter plate wells, and inhibitors were added from stock solutions in DMSO, such that the final DMSO concentration was 1%. Novobiocin and clorobiocin were used as controls. After incubation of the microtiter plates at 37°C for 5 h, the A₅₉₅ and the bioluminescence were determined. For normalization of the light output with the bacterial growth, the light output was divided by the OD of the culture at 595 nm. The induction factors for a certain reporter gene construct with a given antibacterial compound were obtained by dividing the normalized light output in the presence of a compound through the normalized output in the absence of the compound.

MIC determination. The broth microdilution procedure recommended by the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) (28) was used for determination of the MICs. The following strains were used: (i) strains with unaltered permeability, which included Staphylococcus aureus ATCC 29213, Streptococcus pneumoniae ATCC 49619, E. coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, and Entercococcus faecalis ATCC 29212 (28); Staphylococcus aureus 80CR5 (7); E. coli UB1005 (5); Pseudomonas aeruginosa K799 (wild type) (5, 19); and Streptococcus pneumoniae TUPELO (26) and (ii) hyperpermeable strains E. coli DC2 and Pseudomonas aeruginosa K799/61 (5). All test strains were obtained from the bacterial collection of Basilea Pharmaceutica AG (Basel, Switzerland). The MICs were determined as described previously (10).

For testing of the aminocoumarins, were dissolved in DMSO; the maximum final concentration of DMSO in the assays was 2% (vol/vol). All the bacteria grew well in 2% DMSO in the absence of antibiotics.

In silico docking studies. The binding energies of the aminocoumarin structures to the GyrB subunit were calculated by using Moloc software (www.moloc.ch). First, the compounds were docked manually by using the structure of the E. coli GyrB 24-kDa domain in complex with clorobiocin (PDB code 1kzn) (16). If applicable, a binding mode similar to that of clorobiocin was used as the starting point. Subsequently, the complexes were optimized by using Moloc software with standard force field and optimization parameters. The positions of the protein residues and water molecules were kept invariable. The calculated binding energies were corrected by the energy term related to the conformational strain. This energy term was estimated from the differences between the conformational energies of the compounds in the predicted binding conformation and after optimization in vacuum.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Panel of test compounds. The 31 aminocoumarin compounds tested in this study are listed in Table 1. In contrast to the 3-dimethylallyl-4-hydroxybenzoyl moiety (ring A) of clorobiocin, they contained 11 different structural analogs of that moiety. Other structural differences from the structure of clorobiocin included the nature of the substituent at position 8' of the aminocoumarin moiety, representing either chlorine, methyl, or hydrogen, and the position of the acyl substituent at the deoxysugar, being attached either to the 3''-OH group or to the 2''-OH group. All these compounds were derived from mutasynthetic feeding experiments, and the structures of all compounds have been confirmed by nuclear magnetic resonance and mass spectrometry (1, 2). Compounds 241, 311, 312, and 313 have been identified and partially investigated for their biological activities in previous studies (10), whereas the other 27 compounds were investigated here for the first time.

View this table: [in this window] [in a new window]

TABLE 1. Chemical structures of the compounds tested

Activities against Escherichia coli DNA gyrase. The test compounds were investigated in vitro for their inhibitory effects on E. coli DNA gyrase in comparison with the inhibitory effects of the natural antibiotics novobiocin and clorobiocin. Two different assays were used: an ATPase assay and a supercoiling assay.

The ATPase assay measured the ATP hydrolyzing activity of the B subunit of E. coli DNA gyrase and its inhibition by aminocoumarin antibiotics (25). The assay buffer contained ATP, the gyrase subunit B, and different concentrations of the respective aminocoumarin. The supercoiling assay, based on DNA triplex formation (24), measured the activity of the intact E. coli gyrase heterotetramer.

All 31 test compounds were investigated by use of the ATPase assay. In accordance with previously reported results (8, 10), the five compounds lacking a pyrrole unit attached to the deoxysugar (i.e., novclobiocin compounds 204, 219, 315, 606, and 704) were found to be completely inactive. Therefore, these compounds were excluded from further investigation. Three compounds (novclobiocin compounds 372, 604, and 703) were not available in sufficient amounts, so 23 compounds were also investigated by use of the supercoiling assay.

Table 2 shows the 50% inhibitory concentrations (IC₅₀s) obtained by both assays as well as the ratios of the values from the two assays. In Table 2, the compounds are ranked according to their activities in the ATPase assay. As is immediately obvious, the rank order of activities obtained by both assays was similar; however, the absolute IC₅₀s obtained by the two assays showed clear differences (see Discussion).

View this table: [in this window] [in a new window]

TABLE 2. IC50s determined by ATPase and triplex formation assays

In both assays, novclobiocin compounds 201 and 601 were the most active of the new compounds, with novclobiocin compounds 217 and 371 being only slightly less active. These four compounds carried completely different analogs of the ring A moiety: novclobiocin compound 201 carried a 3,5-dimethyl-4-hydroxybenzoyl group, novclobiocin compound 601 carried a benzoyl group, novclobiocin compound 217 carried a 3-propyl-4-hydroxybenzoyl group, and novclobiocin compound 371 carried a 4-methylthiobenzoyl group. These results support earlier observations (16) that the ring A moiety lies outside of the principal binding pocket and makes only weak interactions with the bacterial gyrase, allowing considerable structural variability without a loss of activity.

The position of the 5-methylpyrrole moiety at the deoxysugar is very important for activity. Compounds carrying this group at position 3'' of the deoxysugar were, on average, sevenfold more active in the ATPase assay than the corresponding compounds which carried the 5-methylpyrrole moiety at position 2''.

In contrast, it was of minor importance whether the position 8' of the aminocoumarin moiety was substituted by a methyl group or a chlorine atom. Both kinds of compounds showed similar IC₅₀s in the ATPase assay (novclobiocin compound 311 versus novclobiocin compound 314, novclobiocin compound 601 versus novclobiocin compound 604, and novclobiocin compound 701 versus novclobiocin compound 703). However, if there was no substituent at position 8' of the aminocoumarin moiety, the activity was consistently lower than for the methyl- or chlorine-substituted compounds (novclobiocin compound 201 versus novclobiocin compound 203, novclobiocin compounds 311 and 314 versus novclobiocin compound 313, and novclobiocin compounds 601 and 604 versus novclobiocin compound 603).

Reporter gene assays with gyrA and sulA promoter fusions. To further investigate the mode of action of the new aminocoumarin antibiotics, two cell-based reporter gene assays that used fusions of the luxCDABE operon to the gyrA or the sulA promoter, respectively, were used (see Introduction).

As shown in Fig. 2, increasing concentrations of novobiocin and clorobiocin resulted in increasing growth inhibition (decreasing OD). At concentrations of the antibiotic that caused marked but not complete growth inhibition, a strong induction of light emission was observed both from the gyrA promoter fusion and from the sulA promoter fusion. As expected, the concentrations required differed according to the potency of the inhibitor. For example, in order to reach at least a fourfold induction of light emission, 3 to 6 µM of novobiocin but only 0.8 to 1.6 µM of clorobiocin were required. Higher concentrations of novobiocin further increased the induction, until at concentrations of 50 to 100 µM, light emission was reduced due to the effect of the antibiotic on cell viability. Higher concentrations of clorobiocin, in contrast, quickly reduced growth and light emission, reflecting the fact that clorobiocin is an extremely potent inhibitor of two vital targets in the cell, gyrase and topoisomerase IV (8).

View larger version (18K): [in this window] [in a new window]

FIG. 2. Growth inhibition and reporter gene induction in the gyrA and sulA reporter gene assays. See the text for explanations.

The new aminocoumarin compounds, which were active as gyrase inhibitors in vitro, also showed induction of the gyrA and sulA promoters in the reporter gene assays. Figure 2 shows, as examples, the light emission and growth inhibition curves of a highly active inhibitor (novclobiocin compound 601), a less potent inhibitor (novclobiocin compound 603) and an inactive compound (novclobiocin compound 606).

Table 2 lists for each of the new aminocoumarins the lowest test concentration which resulted in at a least fourfold induction of light emission in the respective assay. With very few exceptions, there was a good correlation between the gyrase inhibitory activities in vitro and the gyrA and sulA promoter-inducing activities in the cell-based reporter gene assay. This confirms that nearly all test compounds were active as gyrase inhibitors in the bacterial cell. Only a very few compounds with inhibitory activities in the ATPase assay showed a low level of or no activity in the cell-based reporter gene assays, e.g., novclobiocin compound 203, which also showed a low level of antistaphylococcal activity (see Table 4). The reason for the low level of in vivo activity of novclobiocin compound 203 is unknown. Therefore, the reporter gene assays, which require minimal amounts of the respective antibiotic and which can be carried out in an automated fashion, are suitable for the screening for novel gyrase inhibitors, although they may not detect every compound which shows some gyrase inhibition in vitro.

View this table: [in this window] [in a new window]

TABLE 4. Effects of the new derivatives on growth of selected microorganisms

In silico docking studies and correlation with experimentally obtained activities. The energies of binding of a subset of the new aminocoumarin structures to the GyrB subunit were calculated by using Moloc software (www.moloc.ch). As the first step, the compounds were docked manually by using the structure of the E. coli GyrB 24-kDa domain in complex with clorobiocin (PDB code 1kzn) (16). Interestingly, no suitable initial binding mode was found for derivatives acetylated in position 2'' of the deoxysugar sugar; therefore, these compounds were omitted from the calculation. Subsequently, the complexes were optimized by using Moloc software (see Materials and Methods). The results are summarized in Table 3.

View this table: [in this window] [in a new window]

TABLE 3. Calculated binding energies of selected structures

Low binding energies (i.e., high negative numbers) reflect the tight binding of the compound to the bacterial gyrase. As a consequence, a compound with a low binding energy should also have a low IC₅₀. Comparison of the experimental values (Table 2) and the calculated values (Table 3) indicates that the majority of the compounds were correctly classified as stronger or weaker inhibitors. For example, the calculated binding energy of novclobiocin compound 219, which does not carry an acyl moiety at the deoxysugar, was clearly higher than that of the other compounds, reflecting the inactivity of this compound in the ATPase assay. An exception is compound 201, which showed high activity in the ATPase and supercoiling assays, while only weak binding to GyrB was predicted for this compound in silico. Analysis of the uncorrected energy values indicates that this is most likely based on the overestimation of the energy term for conformational strain.

Antibacterial activities of the new compounds. The MICs of 13 compounds, available in sufficient amounts, against a panel of clinically relevant gram-positive and gram-negative bacteria were determined (Table 4).

Six of the new compounds showed MICs of 0.25 µg/ml for Staphylococcus aureus ATCC 29213. Even against methicillin-resistant strain Staphylococcus aureus ATCC 43300, similar activities were found. Novobiocin resistance is very uncommon in staphylococci (14), but nevertheless, we included novobiocin-resistant strain Staphylococcus aureus 80CR5 in our test panel. However, the new compounds were not active against this strain.

Most of the compounds tested also showed a certain amount of activity against Streptococcus pneumoniae strains, including S. pneumoniae SL336-T (which is resistant to erythromycin) and S. pneumoniae TUPELO (which is resistant to vancomycin). Of the two enterococcal strains tested, only Entercoccus faecalis ATCC 29212 was weakly affected by the new aminocoumarins. In contrast, Enterococcus faecium ATCC 19434 was resistant to all the compounds tested.

As expected (10), the aminocoumarins showed only poor activities against the gram-negative strains E. coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Only the hyperpermeable and efflux-defective strain P. aeruginosa K799/61 (19) was sensitive, in clear contrast to the parental strain P. aeruginosa K799/WT. The hyperpermeable strain E. coli DC2 (5) showed only low sensitivity.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
In the present study, we compared a panel of new gyrase inhibitors, prepared by mutasynthesis, using in vitro assays, reporter gene assays, and antibacterial activity testing.

The ATPase assay, which measured the inhibition of the GyrB-catalyzed hydrolysis of ATP, was adopted from a published method for measuring the inhibition of the ATPase activity of heat shock protein 90 (35) and provided a rapid, easily automated first screen. The supercoiling assay, based on the differential formation of DNA triplexes in supercoiled versus relaxed DNAs (24), measures the supercoiling activity of the intact gyrase heterotetramer. In contrast to conventional supercoiling assays, which measure gyrase activity by the gel electrophoretic mobilities of relaxed and supercoiled plasmids, the triplex formation assay offers the advantage that it is sensitive over the full range of superhelical densities and is much easier to quantitate (24). As shown in Table 2, both the ATPase and the supercoiling assays provided a very similar rank order for the new compounds regarding their potencies as gyrase inhibitors. The absolute IC₅₀s, however, were clearly different for both assays, reflecting differences in the reaction conditions and protein concentrations used in the assays. It should be noted that the IC₅₀s determined for the gyrase inhibitors are strongly dependent on assay conditions, and this problem is especially prominent for the aminocoumarin antibiotics. Therefore, the published values for the IC₅₀s of the aminocoumarins vary considerably between different studies (8, 13, 17, 29). Our study shows that both biochemical assays used in this study are suitable for the screening of gyrase inhibitors but that the inhibitory concentrations obtained in both assays cannot be directly compared.

The gyrA reporter gene assay responds to changes in the superhelical density of DNA in the bacterial cell, caused by gyrase inhibition. Therefore, it can be used to screen for inhibitors that attack at either subunit of gyrase. The inhibition of gyrase affects DNA replication and therefore leads to the induction of the sulA promoter (36). The results from the gyrA and sulA reporter gene assays (Table 2) therefore showed a close correlation to each other and also correlated quite well with the data from the in vitro assays. Luciferase genes are now widely used reporter genes in prokaryotic and eukaryotic systems because they provide a simple approach for the real-time detection of gene expression and regulation (11). The use of the five-gene luxCDABE operon from Photorhabdus luminescens allows facile monitoring of kinetic responses because all components necessary for light production are present in the cell, thus obviating the need for cell lysis and substrate addition (27).

To investigate whether the new compounds have a binding mode similar to that of clorobiocin, the experimentally determined data were compared with the energies of binding to E. coli GyrB calculated in silico. The comparison shows that the calculated binding energies correctly rank the affinities of the majority of the compounds, which indicates that the compounds with the pyrrole moiety in position 3'' of the deoxysugar most probably follow the binding mode observed for clorobiocin. In contrast, the prediction of binding energies was not possible for the compounds with the pyrrole moiety in position 2'' of the deoxysugar. For these compounds, no binding mode which follows the typical pattern of interaction with the aspartate residue and water molecules could be identified (16). This observation indicates that these compounds could have untypical binding modes.

MICs were determined against Staphylococcus and Streptococcus strains as well as other relevant pathogens. The most active antistaphylococcal compounds, besides clorobiocin, were novclobiocin compounds 217 and 225, which contain nonpolar alkyl side chains attached to their benzoyl moieties. However, novclobiocin compounds 201, 314, 371, and 731, which contain ring A analogs which are structurally quite different from the genuine ring A, were also highly active, with their activities equaling or even exceeding the activity of the clinically introduced novobiocin. In contrast, novclobiocin compound 241, which also showed good in vitro activity in the ATPase and supercoiling assays as well as in the reporter gene assay, showed clearly lower antistaphylococcal activity. Since novclobiocin compound 241 contains a polar side chain attached to the benzoyl moiety, this observation may confirm earlier speculations that the nonpolar side chain attached to the benzoyl moiety of novobiocin and clorobiocin may be important for the uptake of these antibiotics into bacteria (17). Interestingly, compounds which carried cinnamic acid or 3-methoxy-4-hydroxycinnamic acid as ring A analogs (novclobiocin compounds 701 and 731) showed quite high levels of activity against staphylococci. At least for novclobiocin compound 731, this was not predicted by the in vitro activity against E. coli gyrase in the ATPase assay (Table 2). Replacement of the chlorine atom at position 8' of the aminocoumarin moiety of novclobiocin compound 201 with a proton (which gave novclobiocin compound 203) resulted in clearly reduced antibacterial activity (novclobiocin compounds 201 and 203).

 
We thank S. Shapiro (Basilea Pharmaceutica AG, Basel, Switzerland) for the determination of the MICs.

This work was supported by a grant from the European Community (IP no. 005224 ActinoGEN).

 
* Corresponding author. Mailing address: Pharmazeutische Biologie, Pharmazeutisches Institut, Universität Tübingen, Auf der Morgenstelle 8, Tübingen D-72076, Germany. Phone: 49-7071-29-72460. Fax: 49-7071-29-5250. E-mail: heide{at}uni-tuebingen.de

Published ahead of print on 17 March 2008.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1
1. Anderle, C., S. Hennig, B. Kammerer, S. M. Li, L. Wessjohann, B. Gust, and L. Heide. 2007. Improved mutasynthetic approaches for the production of modified aminocoumarin antibiotics. Chem. Biol. 14:955-967.[CrossRef][Medline]
2
2. Anderle, C., S. M. Li, B. Kammerer, B. Gust, and L. Heide. 2007. New aminocoumarin antibiotics derived from 4-hydroxycinnamic acid are formed after heterologous expression of a modified clorobiocin biosynthetic gene cluster. J. Antibiot. (Tokyo) 60:504-510.[Medline]
3
3. Eady, E. A., and J. H. Cove. 2003. Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus—an emerging problem for the management of skin and soft tissue infections. Curr. Opin. Infect. Dis. 16:103-124.[Medline]
4
4. Eder, J. P., C. A. Wheeler, B. A. Teicher, and L. E. Schnipper. 1991. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Res. 51:510-513.[Abstract/Free Full Text]
5
5. el Falaha, B. M., A. D. Russell, and J. R. Furr. 1983. Sensitivities of wild-type and envelope-defective strains of Escherichia coli and Pseudomonas aeruginosa to antibacterial agents. Microbios 38:99-105.[Medline]
6
6. Ellis, G. K., J. Crowley, R. B. Livingston, J. W. Goodwin, L. Hutchins, and A. Allen. 1991. Cisplatin and novobiocin in the treatment of non-small cell lung cancer. A Southwest Oncology Group study. Cancer 67:2969-2973.[Medline]
7
7. Engel, H. W., N. Soedirman, J. A. Rost, W. J. van Leeuwen, and J. D. van Embden. 1980. Transferability of macrolide, lincomycin, and streptogramin resistances between group A, B, and D streptococci, Streptococcus pneumoniae, and Staphylococcus aureus. J. Bacteriol. 142:407-413.[Abstract/Free Full Text]
8
8. Flatman, R. H., A. Eustaquio, S. M. Li, L. Heide, and A. Maxwell. 2006. Structure-activity relationships of aminocoumarin-type gyrase and topoisomerase IV inhibitors obtained by combinatorial biosynthesis. Antimicrob. Agents Chemother. 50:1136-1142.[Abstract/Free Full Text]
9
9. Frackman, S., M. Anhalt, and K. H. Nealson. 1990. Cloning, organization, and expression of the bioluminescence genes of Xenorhabdus luminescens. J. Bacteriol. 172:5767-5773.[Abstract/Free Full Text]
10
10. Galm, U., S. Heller, S. Shapiro, M. Page, S. M. Li, and L. Heide. 2004. Antimicrobial and DNA gyrase-inhibitory activities of novel clorobiocin derivatives produced by mutasynthesis. Antimicrob. Agents Chemother. 48:1307-1312.[Abstract/Free Full Text]
11
11. Hakkila, K., M. Maksimow, M. Karp, and M. Virta. 2002. Reporter genes lucFF, luxCDABE, gfp, and dsred have different characteristics in whole-cell bacterial sensors. Anal. Biochem. 301:235-242.[CrossRef][Medline]
12
12. Hallett, P., A. J. Grimshaw, D. B. Wigley, and A. Maxwell. 1990. Cloning of the DNA gyrase genes under tac promoter control: overproduction of the gyrase A and B proteins. Gene 93:139-142.[CrossRef][Medline]
13
13. Hooper, D. C., J. S. Wolfson, G. L. McHugh, M. B. Winters, and M. N. Swartz. 1982. Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth. Antimicrob. Agents Chemother. 22:662-671.[Abstract/Free Full Text]
14
14. Jones, R. N. 1989. Should novobiocin be clinically re-evaluated? Diagn. Microbiol. Infect. Dis. 12:363-365.[CrossRef][Medline]
15
15. Kirby, W. M., D. G. Hudson, and W. D. Noyers. 1956. Clinical and laboratory studies of novobiocin, a new antibiotic. AMA Arch. Intern. Med. 98:1-7.[Medline]
16
16. Lafitte, D., V. Lamour, P. O. Tsvetkov, A. A. Makarov, M. Klich, P. Deprez, D. Moras, C. Briand, and R. Gilli. 2002. DNA gyrase interaction with coumarin-based inhibitors: the role of the hydroxybenzoate isopentenyl moiety and the 5'-methyl group of the noviose. Biochemistry 41:7217-7223.[CrossRef][Medline]
17
17. Laurin, P., D. Ferroud, M. Klich, C. Dupuis-Hamelin, P. Mauvais, P. Lassaigne, A. Bonnefoy, and B. Musicki. 1999. Synthesis and in vitro evaluation of novel highly potent coumarin inhibitors of gyrase B. Bioorg. Med. Chem. Lett. 9:2079-2084.[CrossRef][Medline]
18
18. Lewis, R. J., F. T. F. Tsai, and D. B. Wigley. 1996. Molecular mechanisms of drug inhibition of DNA gyrase. Bioessays 18:661-671.[CrossRef][Medline]
19
19. Li, X. Z., D. M. Livermore, and H. Nikaido. 1994. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob. Agents Chemother. 38:1732-1741.[Abstract/Free Full Text]
20
20. Lorico, A., G. Rappa, and A. C. Sartorelli. 1992. Novobiocin-induced accumulation of etoposide (VP-16) in WEHI-3B D⁺ leukemia cells. Int. J. Cancer 52:903-909.[Medline]
21
21. Marcinak, J. F., and A. L. Frank. 2003. Treatment of community-acquired methicillin-resistant Staphylococcus aureus in children. Curr. Opin. Infect. Dis. 16:265-269.[Medline]
22
22. Marcu, M. G., A. Chadli, I. Bouhouche, M. Catelli, and L. M. Neckers. 2000. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 275:37181-37186.[Abstract/Free Full Text]
23
23. Marcu, M. G., T. W. Schulte, and L. Neckers. 2000. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J. Natl. Cancer Inst. 92:242-248.[Abstract/Free Full Text]
24
24. Maxwell, A., N. P. Burton, and N. O'Hagan. 2006. High-throughput assays for DNA gyrase and other topoisomerases. Nucleic Acids Res. 34:e104.[Abstract/Free Full Text]
25
25. Maxwell, A., and D. M. Lawson. 2003. The ATP-binding site of type II topoisomerases as a target for antibacterial drugs. Curr. Top. Med. Chem. 3:283-303.[CrossRef][Medline]
26
26. McCullers, J. A., B. K. English, and R. Novak. 2000. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J. Infect. Dis. 181:369-373.[CrossRef][Medline]
27
27. Meighen, E. A. 1991. Molecular biology of bacterial bioluminescence. Microbiol. Rev. 55:123-142.[Abstract/Free Full Text]
28
28. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th edition, and Performance standards for antimicrobial susceptibility testing, 16th informational supplement. National Committee for Clinical Laboratory Standards, Wayne, PA.
29
29. Peng, H., and K. J. Marians. 1993. Decatenation activity of topoisomerase IV during oriC and pBR322 DNA replication in vitro. Proc. Natl. Acad. Sci. USA 90:8571-8575.[Abstract/Free Full Text]
30
30. Perronne, C. M., R. Malinverni, and M. P. Glauser. 1987. Treatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combination. Antimicrob. Agents Chemother. 31:539-543.[Abstract/Free Full Text]
31
31. Pitlik, S. 2003. Old drugs for new bugs. BMJ 326:235-236.[Free Full Text]
32
32. Raad, I., R. Darouiche, R. Hachem, M. Sacilowski, and G. P. Bodey. 1995. Antibiotics and prevention of microbial colonization of catheters. Antimicrob. Agents Chemother. 39:2397-2400.[Abstract]
33
33. Raad, I. I., R. Y. Hachem, D. Abi-Said, K. V. I. Rolston, E. Whimbey, A. C. Buzaid, and S. Legha. 1998. A prospective crossover randomized trial of novobiocin and rifampin prophylaxis for the prevention of intravascular catheter infections in cancer patients treated with interleukin-2. Cancer 82:403-411.[CrossRef][Medline]
34
34. Rappa, G., A. Lorico, and A. C. Sartorelli. 1992. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26). Int. J. Cancer 51:780-787.[Medline]
35
35. Rowlands, M. G., Y. M. Newbatt, C. Prodromou, L. H. Pearl, P. Workman, and W. Aherne. 2004. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal. Biochem. 327:176-183.[CrossRef][Medline]
36
36. Shapiro, E., and F. Baneyx. 2002. Stress-based identification and classification of antibacterial agents: second-generation Escherichia coli reporter strains and optimization of detection. Antimicrob. Agents Chemother. 46:2490-2497.[Abstract/Free Full Text]
37
37. Walsh, T. J., S. L. Hansen, B. A. Tatem, F. Auger, and H. C. Standiford. 1985. Activity of novobiocin against methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 15:435-440.[Abstract/Free Full Text]
38
38. Walsh, T. J., H. C. Standiford, A. C. Reboli, J. F. John, M. E. Mulligan, B. S. Ribner, J. Z. Montgomerie, M. B. Goetz, C. G. Mayhall, D. Rimland, D. A. Stevens, S. L. Hansen, G. C. Gerard, and R. J. Ragual. 1993. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob. Agents Chemother. 37:1334-1342.[Abstract/Free Full Text]

---

Antimicrobial Agents and Chemotherapy, June 2008, p. 1982-1990, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.01235-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Anderle, C. Articles by Heide, L. Search for Related Content PubMed PubMed Citation Articles by Anderle, C. Articles by Heide, L.